CVS/CAREMARK

[Anonymous]

If your looking into this company run away

 

[Anonymous]

If your looking into this company run away

Yes, I agree. Stay away, we don't want you. Knucklehead.

 

[Anonymous]

Yes, I agree. Stay away, we don't want you. Knucklehead.

Another kool aid drinking jerk, probably a pharma reject, or a loser who couldn't find any other job

 

[anonymous]

Get ready for another major CVS acquisition.

 

[anonymous]

Another kool aid drinking jerk, probably a pharma reject, or a loser who couldn't find any other job

Knucklehead

 

[anonymous]

Another kool aid drinking jerk, probably a pharma reject, or a loser who couldn't find any other job

Typical knucklehead response.

 

[anonymous]

Run away 50% of the sales force nationally have left the Autoimmune division in the last year, 7 in the east alone. What does that tell you?

 

[anonymous]

Run away 50% of the sales force nationally have left the Autoimmune division in the last year, 7 in the east alone. What does that tell you?

7 in the East. What does THAT tell you?

 

[anonymous]

7 in the East. What does THAT tell you?

Dead weight anyways

 

[anonymous]

Why are they leaving? What's up with that division?

 

[anonymous]

Why are they leaving? What's up with that division?

expansion

 

[anonymous]

Run away 50% of the sales force nationally have left the Autoimmune division in the last year, 7 in the east alone. What does that tell you?

They're all knuckleheads

 

[anonymous]

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/318bef8a-88fe-495a-ba4c-917fb133be6b

Several of the biggest US pharmacy benefit managers have generated more than $7.3bn in revenue by charging “enormous mark-ups” for drugs treating cancer and HIV, according to the US Federal Trade Commission. A report published by the competition regulator on Tuesday named CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth Group’s Optum, which administer about 80 per cent of all prescriptions in the US.

 

[anonymous]

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/318bef8a-88fe-495a-ba4c-917fb133be6b

Several of the biggest US pharmacy benefit managers have generated more than $7.3bn in revenue by charging “enormous mark-ups” for drugs treating cancer and HIV, according to the US Federal Trade Commission. A report published by the competition regulator on Tuesday named CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth Group’s Optum, which administer about 80 per cent of all prescriptions in the US.

Pssst

Nobody cares.